Clinical Trials Logo
  1. Home
  2. Overactive Bladder (OAB)
  3. NCT00507169
  4. Details
NCT00507169 Clinical Trial

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Overactive Bladder (OAB) Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00507169
Other study ID # 40776ORII/05IA01
Secondary ID
Status Completed
Phase Phase 2
First received July 25, 2007
Last updated June 7, 2011
Start date September 2006
Est. completion date September 2007

Study information
Verified date June 2011
Source Salvat
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date September 2007
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

- Pregnant and breastfeeding women

- Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• SVT-40776

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Salvat
See also
  Status Clinical Trial Phase
Completed NCT02216214 - Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Phase 4
Completed NCT02294396 - Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Phase 4
Completed NCT01936870 - Drug Use Investigation for Toviaz
Completed NCT03846895 - Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) N/A
Completed NCT03903094 - A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Terminated NCT04451382 - PTNS vs Botox of Refractory OAB
Terminated NCT04641975 - A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) Phase 3
Completed NCT00366002 - Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Phase 4
Completed NCT02138747 - A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Phase 4
Completed NCT03602508 - Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Completed NCT03572231 - A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
Completed NCT05211193 - Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
Completed NCT04562090 - A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder Phase 4
Completed NCT00282932 - Detrol LA In Men With Overactive Bladder. Phase 4
Completed NCT01639794 - Vesitirim™ in Men Postmarketing Observational Study N/A
Completed NCT00742833 - A Phase II Study of KUC-7483 in Patients With Overactive Bladder Phase 2
Withdrawn NCT01317810 - A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication N/A